Lipopeptide inhibitors of fungal glucan synthase

Journal of Medical and Veterinary Mycology

Volumn 35, Issue 2, 1997, Pages 79-86

  Kurtz, M B ^a   Douglas, C M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Fungal glucan synthetase; Lipopeptide inhibitors

Indexed keywords

ACULEACIN; ANIDULAFUNGIN; ECHINOCANDIN B; ENZYME INHIBITOR; GLUCAN SYNTHASE; GLUCAN SYNTHASE INHIBITOR; L 733560; LY 280949; PAPULACANDIN; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; ENZYME INHIBITION; NONHUMAN; REVIEW; SACCHAROMYCES CEREVISIAE; SPOROGENESIS; VETERINARY MEDICINE;

CANDIDA ALBICANS; FUNGI; SACCHAROMYCES CEREVISIAE;

EID: 0030943354     PISSN: 02681218     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-30.
2. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
3. Roder BL, Sonnenschein C, Hartzen SH. Failure of fluconazole therapy in Candida krusei fungemia. Eur J Clin Microbiol Infect Dis 1991; 10: 173.
4. Tam JY, Blume KG, Prober CG. Prophylactic fluconazole and Candida krusei infections. N Engl J Med 1992; 326: 891.
5. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-7.
6. Kang MS, Cabib E. Regulation of fungal cell wall growth: a guanine nucleotide-binding, proteinaceous component required for activity of (1,3)-β-D-glucan synthase. Proc Natl Acad Sci USA 1986; 83: 5808-12.
7. Awald P, Zugel M, Monks C, Frost D, Selitrennikoff CP. Purification of 1,3-β-glucan synthase from Neurospora crassa by product entrapment. Exp Mycol 1993; 17: 130-41.
8. Inoue SB, Takewaki N, Takasuka T, et al. Characterization and gene cloning of 1,3-β-D-glucan synthase from Saccharomyces cerevisiae. Eur J Biochem 1995; 231: 845-54.
9. Mol PC, Park HM, Mullins JT, Cabib E. A GTP-binding protein regulates the activity of (1-3)-β-glucan synthase, an enzyme directly involved in yeast cell wall morphogenesis. J Biol Chem 1994; 269: 31267-74.
10. Kelly R, Register E, Hsu M-J, Kurtz M, Nielsen J. Isolation of a gene involved in 1,3-β-glucan synthesis in Aspergillus nidulans and purification of the corresponding protein. J Bacteriol 1996; 178: 4381-91.
11. Goldman RC, Frost DJ, Capobianco JO, et al. Antifungal drug targets: Candida secreted aspartyl protease and fungal wall β-glucan synthesis. Infect Agents Dis 1995; 4: 228-47.
12. Balkovec JM. Lipopeptide antifungal agents. Exp Opin Invest Drugs 1994; 3: 65-82.
13. Cid VJ, Duran A, del Rey F, et al. Molecular basis of cell integrity and morphogenesis in Saccharomyces cerevisiae. Microbiol Rev 1995; 59: 345-86.
14. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994; 48: 471-97.
15. Fromtling RA, Castaner J. LY-303366. Drugs of the Future 1994; 19: 338-42.
16. Georgopapadakou NH, Tkacz JS. The fungal cell wall as a drug target. Trends Microbiol 1995; 3: 98-104.
17. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993; 6: 1-21.
18. Rommele G, Traxler P, Wehrli W. Papulacandins: the relationship between chemical structure and effect on glucan synthesis in yeast. J Antibiot 1983; 36: 1539-42.
19. Yeung CM, Klein LL, Lartey PA. Preparation and antifungal activity of fusacandin analogs: C-6′ sidechain esters. Bioorg Med Chem Lett 1996; 6: 819-22.
20. Debono M, Turner WW, LaGrandeur L, et al. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J Med Chem 1995; 38: 3271-3281.
21. 0 derivatives. J Med Chem 1994; 37: 222-5.
22. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of water soluble pneumocandin analogs L-733,560, L-705,589, and L-731, 373 with mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob Agents Chemother 1995; 39: 1077-81.
23. Kurtz MB, Douglas C, Marrinan J, et al. Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother 1994; 38: 2750-7.
24. Schmatz DM, Powles MA, McFadden D, et al. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Antimicrob Agents Chemother 1995; 39: 1320-3.
25. Zeckner D, Butler T, Boylan C, et al. LY303366 activity against systemic aspergillosis and histoplasmosis in murine models. Abstract 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LO 1993, Abstract 364.
26. Kurtz MB, Bernard EM, Edwards FF, et al. Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1995; 39: 1784-9.
27. Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-9.
28. Beaulieu D, Tang J, Yan SB, et al. Characterization and cilofungin inhibition of solubilized Aspergillus fumigatus (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 937-44.
29. Beaulieu D, Tang J, Zeckner DJ, Parr TR. Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-β-D-glucan synthase. FEMS Microbiol Lett 1993; 108: 133-7.
30. Douglas CM, Marrinan JA, Li W, Kurtz MB. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-β-D glucan synthase. J Bacterial 1994; 176: 5686-96.
31. el-Sherbeini M, Clemas JA, Nikkomycin Z supersensitivity of an echinocandin-resistant mutant of Saccharomyces cerevisiae. Antimicrob Agents Chemother 1995; 39: 200-7.
32. Eng WK, Faucette L, Mclaughlin MM, et al. The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth. Gene 1994; 151: 61-71.
33. Castro C, Ribas JC, Valdivieso MH, et al. Biosynthesis of the yeast cell wall. PBR1, a gene involved in papulacandin B sensitivity, is required for (1,3)β-D-glucan synthesis. Yeast 1995; 11: S327.
34. Dixon CK, Ma D. Characterization of ECB LY280949 resistant mutants in Saccharomyces cerevisiae. Yeast 1995; 11: S538.
35. Ram AF, Brekelmans SS, Oehlen LJ, Klis FM. Identification of two cell cycle-regulated genes affecting the β-1,3-glucan content of cell walls in Saccharomyces cerevisiae. FEBS Lett 1995; 358: 165-70.
36. Ram AF, Wolters A, Tenhoopen R, Klis FM. A new approach for isolating cell-wall mutants in Saccharomyces cerevisiae by screening for hypersensitivity to calcofluor white. Yeast 1994; 10: 1019-30.
37. + -ATPase. Mol Cell Biol 1995; 15: 4103-14.
38. Douglas CM, Foor F, Marrinan JA, et al. The Saccharomyces cerevisiae FKS1(ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. Proc Natl Acad Sci USA 1994; 91: 12907-11.
39. Mazur P, Morin N, Baginsky W, et al. Differential expression and function of two homologous subunits of yeast 1,3-β-D-glucan synthase. Mol Cell Biol 1995; 15: 5671-81.
40. Mitchell A, Douglas C, d'Ippolito J, Shei GJ, Kurtz MB. Homology of genes that confer echinocandin resistance in Saccharomyces cerevisiae and Candida albicans. Abstract 133 1995 Yeast Cell Biology Meeting, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1995.
41. el-Sherbeini M, Clemas JA. Cloning and characterization of GNS1 - a Saccharomyces cerevisiae gene involved in synthesis of 1,3-β-glucan in vitro. J Bacterial 1995; 177: 3227-34.
42. Hong Z, Mann P, Brown NH, et al. Cloning and characterization of KNR4, a yeast gene involved in (1,3)-β-glucan synthesis. Mol Cell Biol 1994; 14: 1017-25.
43. Kasahara S, Yamada H, Mio T, et al. Cloning of the Saccharomyces cerevisiae gene whose overexpression overcomes the effects of H-M1 killer toxin, which inhibits β-glucan synthesis. J Bacteriol 1994; 176: 1488-99.
44. Drgonova J, Drgon T, Tanaka K, et al. Rho1p, a yeast protein at the interface between cell polarization and morphogenesis. Science 1996; 272(5259): 277-9.
45. Mazur P, Baginsky W. In vitro activity of the 1,3-β-D-glucan synthase requires the GTP-binding protein Rhol. J Biol Chem 1996; 271: 14604-9.
46. Qadota H, Python CP, Inoue SB, et al. Identification of yeast Rholp GTPase as a regulatory subunit of 1,3-β-glucan synthase. Science 1996; 272(5259): 279-81.
47. Douglas C, Marrinan J, Nollstadt K, et al. Mode of action of pneumocandin analogs: genetic and virulence studies with Candida albicans. Abstract XII Congress of International Society of Human and Animal Mycology 1994, Abstract PO2.28 (D91).
48. Kurtz MB, Abruzzo GK, Flattery AM, et al. Isolation and characterization of echinocandin resistant mutants of Candida albicans: genetic, biochemical and virulence studies. Yeast 1995; 11: S561.
49. Beckford LM, Kerridge D. The effect of echinocandin B and cilofungin on the activity of β-(1,3)-glucan synthetase in sensitive and resistant strains of Candida. Abstract XI Congress International Society of Human and Animal Mycology 1991, Abstract P53.11.
50. Cassone A, Mason RE, Kerridge D, Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study. Sabouraudia 1981; 19: 97-110.
51. Kurtz MB, Abruzzo G, Flattery A, et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun 1996; 64: 3244-51.
52. Font de Mora J, Gil R, Sentandreu R, Herrero E. Isolation and characterization of Saccharomyces cerevisiae mutants resistant to aculeacin A. Antimicrob Agents Chemother 1991; 35: 2596-601.